Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genomic alterations and their correlation with metabolic-related genes in lung cancer.

Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico - 1 Aug 2026

Gaur Gauri, Jha Niraj Kumar, Gambhir Lokesh, Acharya Seema V, Kumar Dhruv

Abstract excerpt

Non-small cell lung cancer (NSCLC) remains the leading cause of cancer-related mortality worldwide, with 5-year survival rates below 21% primarily due to therapeutic resistance and metastatic progression. Genomic alterations in KRAS, EGFR, TP53, and MYC drive metabolic reprogramming that sustains tumor proliferation and therapy resistance. This review synthesizes evidence linking specific genomic alterations,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Non-Small-Cell Lung
Share to STK11 gene

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genomics

Share to Lung Neoplasms

Share to Mutation

Share to Proto-Oncogene Proteins p21(ras)

Share to Tumor Microenvironment

Share to Tumor Suppressor Protein p53

Source

Identifiers

PMID: 41670818
DOI: 10.1007/s12094-026-04229-4

Genes

KRAS
TP53
EGFR
MYC
STK11

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genomic alterations and their correlation with metabolic-related genes in lung cancer.PMID 41670818Read ↗

Shining a light on metabolic vulnerabilities in non-small cell lung cancer.Semantic proximity Read ↗

Therapeutic strategies of metabolic reprogramming in non-small cell lung carcinoma.Semantic proximity Read ↗

Loss of STK11 Suppresses Lipid Metabolism and Attenuates KRAS-Induced Immunogenicity in Patients with Non-Small Cell Lung Cancer.Semantic proximity Read ↗

Alternative Energy: Breaking Down the Diverse Metabolic Features of Lung CancersSemantic proximity Read ↗

Identified lung adenocarcinoma metabolic phenotypes and their association with tumor immune microenvironment.Semantic proximity Read ↗

Targeting KRAS: from metabolic regulation to cancer treatmentSemantic proximity Read ↗

Oncogene-Driven Metabolic Alterations in CancerSemantic proximity Read ↗

Multimodal Analysis Reveals Differential Immuno-Metabolic Features in Lung Squamous Cell Carcinoma and AdenocarcinomaSemantic proximity Read ↗

Histone Deacetylase 6 Inhibition Exploits Selective Metabolic Vulnerabilities in LKB1 Mutant, KRAS Driven NSCLC.Semantic proximity Read ↗

Targeting GSTZ1 Sensitizes KRASG12C-Mutant Lung Cancer Cells by Overcoming Glutathione and Glycolysis Pathway Rewiring.Semantic proximity Read ↗

Metabolic reprogramming in KRAS-mutant cancers: Proven targetable vulnerabilities and potential therapeutic strategies.Semantic proximity Read ↗

Metabolic reprogramming of carcinoma-associated fibroblasts and its impact on metabolic heterogeneity of tumors.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.